Wide Ranks

INDV

Indivior PLC

11.33

Top Statistics
Market Cap 1 B Forward PE 7.13 Revenue Growth 13.30 %
Current Ratio 0.83 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -0.25 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 4.58 Enterprise / Revenue 1.21 Price To Sales Trailing12 Months 1.21
Profitability
Profit Margins -0.25 % Operating Margins 30.62 %
Balance Sheet
Total Cash 318 M Total Cash Per Share 2.45 Total Debt 284 M
Total Debt To Equity Current Ratio 0.83 Book Value Per Share -1.29
All Measures
Short Ratio 84.00 % Message Board Id finmb_277824630 Shares Short Prior Month 990177
City North Chesterfield Uuid 6ccbc633-9192-373d-a22d-85090b520ee6 Previous Close 11.18
First Trade Date Epoch Utc 1 B Book Value -1.29 Beta 0.2720
Total Debt 284 M Volume 520492 Fifty Two Week Low 7.33
Total Cash Per Share 2.45 Total Revenue 1 B Shares Short Previous Month Date 1 B
Target Median Price 16.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins 30.62 % Target Mean Price 16.00 Net Income To Common -3000000
Short Percent Of Float 0.0081 Implied Shares Outstanding 129 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 318 M Next Fiscal Year End 1 B Revenue Per Share 8.76
Held Percent Insiders 0.0536 Ebitda Margins 26.48 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 11.18
Target Low Price 16.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.56
Open 11.06 Free Cashflow -70875000 State VA
Dividend Yield 0.00 % Return On Assets 0.1127 Time Zone Short Name EST
Trailing Eps -0.0300 Day Low 10.94 Address1 10710 Midlothian Turnpike
Shares Outstanding 126 M Price Hint 2 Target High Price 16.00
Website https://www.indivior.com 52 Week Change -0.3304 Average Volume 1 M
Forward Eps 1.07 Recommendation Key none Quick Ratio 61.20 %
Is_sp_500 False Regular Market Day High 11.47 Profit Margins -0.25 %
Fifty Two Week High 23.22 Day High 11.47 Shares Short 1 M
Regular Market Open 11.06 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 1.21 Revenue Growth 13.30 % Shares Percent Shares Out 0.0080
Operating Cashflow -240000000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 23235
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Ex Dividend Date 1 B
Regular Market Day Low 10.94 Held Percent Institutions 0.8898 Long Name Indivior PLC
Current Price 11.33 Address2 Suite 125 Enterprise To Ebitda 4.58
Financial Currency USD Current Ratio 0.83 Gross Margins 82.40 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 3 Country United States
Float Shares 112 M Two Hundred Day Average 14.65 Enterprise Value 1 B
Price To Sales Trailing12 Months 1.21 Forward PE 7.13 Regular Market Volume 520492
Ebitda 313 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.

The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults.

In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics.

Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose.

It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder.

The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.